Compare BioNTech SE - ADR (BNTX) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Lamb Weston Holdings Inc — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.78B), while Lamb Weston Holdings Inc trades at $46.3 (market cap $6.49B). The key difference: BioNTech SE - ADR is far larger — about 3.5× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 3.24% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | LW | |
|---|---|---|
Market Cap | $22.78B | $6.49B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $66.57 |
52-Week Low | $83.89 | $38.48 |
Enterprise Value | $6.45B | $10.45B |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Lamb Weston (LW) trades at $46.98, up 1.14% with a bullish technical signal and consistent earnings beats. The company shows strong operational cash flow of $868.3M in 2025 and maintains positive revenue growth, though net income margin declined to 4.61%. Recent news highlights the 'Focus to Win' strategy showing early traction with North America volume gains and cost savings.
Outlook remains cautiously optimistic with analyst consensus price target of $49.33 offering 5% upside. Key risks include ongoing securities litigation and margin pressure from competitive dynamics. Institutional sentiment leans positive with activist involvement signaling potential value creation opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
